Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Partial tumor debulking enhances the response to somatostatin analogs in acromegaly

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Holdaway IM et al. (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89: 667–674

    Article  CAS  Google Scholar 

  2. Bevan JS et al. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87: 4554–4563

    Article  CAS  Google Scholar 

  3. Hofland LJ and Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24: 28–47

    Article  CAS  Google Scholar 

  4. Jacquet P et al. (2000) Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85: 781–792

    Google Scholar 

  5. Matrone C et al. (2004) Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 79: 142–148

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrew R Hoffman.

Ethics declarations

Competing interests

Dr Hoffman is on the Scientific Advisory Board of Genentech and Ambrx; a consultant for Genentech, LG Life Sciences, Teva and ConjuChem; has been awarded research grants by Genentech and Pfizer; holds honoraria from Genentech and Pfizer; and owns stock in Ambrx.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffman, A. Partial tumor debulking enhances the response to somatostatin analogs in acromegaly. Nat Rev Endocrinol 2, 424–425 (2006). https://doi.org/10.1038/ncpendmet0223

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0223

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing